The efficacy of the traditional medicine preparation of dodder (Cuscuta campestris Yunck.) and polypody (Polypodium vulgare) in patients with obsessive-compulsive disorde

Phase 3

• Conditions: Obsessive-compulsive disorder.; Obsessive-compulsive disorder

• Registration Number: IRCT20200112046092N1
• Lead Sponsor: Kerman University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 16 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 84

Inclusion Criteria

Age range 18 to 70 years
Practicing obsessive compulsive disorder
Be treated with Fluvoxamine
No alcohol or drugs
Lack of physical illnesses such as: diabetes, hypertension, cardiovascular problems
A score above 21 on the Yale-Brown-OCS criterion
Absence of other psychiatric disorders such as bipolar and psychotic disorders
Absence of mental retardation
Non-pregnancy and lactation

Exclusion Criteria

Drug intolerance
Necessity to take psychiatric drugs other than fluvoxamine or to take measures such as ECT

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of obsessive symptoms. Timepoint: Before starting the treatment and after 4 and 8 weeks of taking the drug, the participants are asked to complete the Yale-Brown questionnaire. Method of measurement: Yale-Brown questionnaire.;Quality of life. Timepoint: Before starting the treatment and after 4 and 8 weeks of taking the drug, the participants are asked to complete the quality of life questionnaire. Method of measurement: quality of life questionnaire.

Secondary Outcome Measures

Name	Time	Method
Determining the effect of gender on the severity of obsessive symptoms and quality of life in patients with obsessive-compulsive disorders treated with fluvoxamine. Timepoint: Before starting treatment and after 4 to 8 weeks of taking the drug. Method of measurement: WHOQOL-BREF questionnaire and Yale-Brown.;Determining the effect of age on the severity of obsessive symptoms and quality of life in patients with obsessive-compulsive disorders treated with fluvoxamine. Timepoint: Before starting treatment and after 4 to 8 weeks of taking the drug. Method of measurement: WHOQOL-BREF questionnaire and Yale-Brown.;Determining the effect of education on the severity of obsessive symptoms and quality of life in patients with obsessive-compulsive disorders treated with fluvoxamine. Timepoint: Before starting treatment and after 4 to 8 weeks of taking the drug. Method of measurement: WHOQOL-BREF questionnaire and Yale-Brown.